Dementia diagnosis and prescription of antidementia drugs: An analysis of German claims data (2006-2016)JOURNAL OF ALZHEIMERS DISEASEIF3.12025-03-010PRE
COVID-19 in the years 2020 to 2022 in Germany: effects of comorbidities and co-medications based on a large-scale database analysisBMC PUBLIC HEALTHIF3.62025-02-080OAAI
N-Nitrosodimethylamine-Contaminated Valsartan and the Risk of Cancer A Longitudinal Cohort Study Based on German Health Insurance DataDEUTSCHES ARZTEBLATT INTERNATIONALIF7.12021-05-2819OA
Glucocorticoid Therapy is Associated with a Lower Risk of DementiaJOURNAL OF ALZHEIMERS DISEASEIF3.12019-11-1812PREAI
REPLY TO: USE OF ANTIEPILEPTIC DRUGS AND DEMENTIA RISK-AN ANALYSIS OF FINNISH HEALTH REGISTER AND GERMAN HEALTH INSURANCE DATAJOURNAL OF THE AMERICAN GERIATRICS SOCIETYIF4.52018-08-090OAAI
Use of Antiepileptic Drugs and Dementia Riskan Analysis of Finnish Health Register and German Health Insurance DataJOURNAL OF THE AMERICAN GERIATRICS SOCIETYIF4.52018-03-2245OAAI
Regular Benzodiazepine and Z-Substance Use and Risk of Dementia: An Analysis of German Claims DataJOURNAL OF ALZHEIMERS DISEASEIF3.12016-09-0643PREAI
Discriminatory power of standard toxicity assays used to evaluate ingredients added to cigarettesREGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52012-02-0120PREAI
Evaluation of the micronucleus assay in bone marrow and peripheral blood of rats for the determination of cigarette mainstream-smoke activityMUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESISIF2.52008-04-0116PREAI
The mouse lymphoma thymidine kinase assay for the assessment and comparison of the mutagenic activity of cigarette mainstream smoke particulate phaseTOXICOLOGYIF4.62006-10-0141PREAI